Antiplatelet regimen after PCI: an ongoing debate

Session comprising selected EuroPCR 2017 abstract submissions

Chairperson: D. Angiolillo

Presentations available when logged in:

  • A novel risk score to predict out-of-hospital bleeding on DAPT
  • Prasugrel, ticagrelor and clopidogrel in primary PCI for STEMI: an analysis of comparative clinical outcomes from the United Kingdom BCIS-NICOR nat...
  • Effects of ticagrelor vs. clopidogrel on myocardial infarct size in patients undergoing primary PCI
  • Ticagelor is not superior to clopidogrel in patients with ACS - A report from SCAAR
  • Patients considered to GP IIb/IIIa antagonists and their follow-up - A longitudinal national multicentre perspective
  • Interaction between coronary stents and length of DAPT: a network meta-analysis of 64 randomised controlled trials and 102,735 patients
  • Impact of platelet reactivity on five-year clinical outcomes following PCI: a landmark analysis
  • Cost-effectiveness of polymer-free drug-coated coronary stents in patients at high bleeding risk: economic evaluation of the LeadersFree trial